Biodexa Pharmaceuticals

Edison Investment Research is terminating coverage on Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

Georgia Capital in 60 seconds

About Edison

About Edison

Careers

Biodexa Pharmaceuticals (NASDAQ: BDRX)

Latest Insights

Biodexa Pharmaceuticals — In a period of transition

Biodexa Pharmaceuticals — Foray into T1D expands business scope

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline

Sector

Research

Midatech Pharma — Announced acquisition to expand portfolio

Midatech Pharma — Patient recruitment begins in rGBM study

Midatech Pharma — Planned dose-escalation commences in rGBM study

Midatech Pharma — MTX110 receives ODD from the EMA for gliomas

Midatech Pharma — Interim DIPG data to be presented at ISPNO

Midatech Pharma — MTX110’s path to market fast-tracked in rGBM

Midatech Pharma — Pipeline delivery key to future outlook

Midatech Pharma: Edison Open House Healthcare 2022

Midatech Pharma — Q-Sphera partnership with Janssen expanded

Midatech Pharma — Pivoting its commercial strategy

Midatech Pharma – Edison Open House interview